Skip to main content
logo
United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
498.65
-15.17 (-2.95%)
Mar 3, 2026, 4:00 PM EST - Market closed

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Tyvaso Revenue
1.88B1.62B
Tyvaso Revenue Growth
15.91%31.34%
Remodulin Revenue
526.80M538.10M
Remodulin Revenue Growth
-2.10%8.75%
Orenitram Revenue
496.90M434.30M
Orenitram Revenue Growth
14.41%20.84%
Unituxin Revenue
226.80M238.70M
Unituxin Revenue Growth
-4.98%20.01%
Adcirca Revenue
30.00M23.80M
Adcirca Revenue Growth
26.05%-17.65%
Total Product Sales Revenue
3.16B2.86B
Total Product Sales Revenue Growth
10.63%23.30%
Revenue (Other)
24.00M22.10M
Revenue (Total)
3.18B2.88B
Revenue (Total) Growth
10.61%23.63%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
3.04B2.74B
United States Revenue Growth
10.85%24.41%
Rest-of-World Revenue
145.70M137.70M
Rest-of-World Revenue Growth
5.81%9.90%
Revenue (Total)
3.18B2.88B
Revenue (Total) Growth
10.61%23.63%

Gross Profit

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Tyvaso Gross Profit
1.64B1.44B
Tyvaso Gross Profit Growth
14.08%32.44%
Remodulin Gross Profit
477.50M490.70M
Remodulin Gross Profit Growth
-2.69%7.47%
Orenitram Gross Profit
468.20M405.90M
Orenitram Gross Profit Growth
15.35%21.09%
Unituxin Gross Profit
209.30M224.30M
Unituxin Gross Profit Growth
-6.69%22.97%
Adcirca Gross Profit
16.90M13.70M
Adcirca Gross Profit Growth
23.36%-17.47%
Total Product Sales Gross Profit
2.81B2.57B
Total Product Sales Gross Profit Growth
9.32%23.89%
Gross Profit (Other)
-14.00M-4.80M
Gross Profit (Total)
2.80B2.57B
Gross Profit (Total) Growth
8.98%24.04%
Updated Feb 25, 2026. Data Source: Fiscal.ai.